Figure 2.
The scheme summarises the mechanisms of action and biomarkers that have been determined (highlights) and those that need further investigation (shadows) related to mCHT. Circulating endothelial cells (CECs); endothelial progenitor cells (EPCs); vascular endothelial growth factor (VEGF); thrombospondin-1 and -2 (TSP-1, and TSP-2); fibroblast growth factor receptors (FGFRs).